MENU

iPSC-CMs: Adult-like Thick-Filament Protein Stoichiometry

bioRxiv
Overview
Human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) exhibit thick-filament protein proportions that closely match adult human myocardium despite overall developmental immaturity. This preservation of stoichiometry supports the use of iPSC-CMs for studying sarcomeric diseases linked to protein dosage, such as MYBPC3-associated hypertrophic cardiomyopathy.
In Depth

Key Findings

Research indicates that human iPSC-derived cardiomyocytes (iPSC-CMs) maintain adult-like stoichiometry of thick-filament proteins. While these cells generally cluster with fetal hearts in terms of their global shared proteome and retain fetal troponin I expression, specific protein ratios within the thick filament remain comparable to those found in adult cardiac regions.

Technical Details

The study utilized an integration of two independent quantitative proteomic datasets of iPSC-CMs, comparing them against published proteomes from fetal and region-resolved adult human hearts. The analysis focused on sarcomeric protein abundance and revealed the following:

  • Myosin heavy-to-light chain ratios approached the expected 2:4 stoichiometry.
  • The abundance of myosin-binding protein relative to myosin heavy chains was comparable across both iPSC-CMs and adult cardiac regions.

Background & Context

iPSC-CMs are known to retain immature sarcomeric isoforms, which has previously raised questions regarding their ability to accurately recapitulate the protein stoichiometry of the adult human myocardium. This study clarifies that developmental immaturity in the expression of sarcomeric isoforms does not necessarily result in altered proportions of thick-filament proteins.

Significance & Outlook

The finding that adult-like myosin-binding protein stoichiometry is preserved in iPSC-CMs provides a technical validation for their use in disease modeling. Specifically, these cells are suitable for investigating sarcomeric diseases associated with altered protein dosage, with a particular application in the study of MYBPC3-associated hypertrophic cardiomyopathy.

Source: https://doi.org/10.64898/2026.11.09.761920

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC